Key facts
- NunaBio’s last known valuation is $16.1M (Mar 2026).
- It has raised $11.3M; the latest was Later Stage VC ($7.6M) in Mar 2026.
- Notable investors include Innovate UK, Ascension, European Regional Development Fund (Brandenburg), Northstar Ventures, Ascension Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for NunaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for NunaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NunaBio
Developer of chemical and biological technologies and products designed to conduct research and development into cell-free DNA synthesis and manufacture DNA. The company offers a range of long and short deoxyribonucleic acid products from microgram through to gram scale, cell therapies, vaccines, diagnostics, gene therapies, and deoxyribonucleic acid biosensing and consumables, enabling healthcare professionals to treat patients using advanced therapeutic methods.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2012
- Employees
- 21
- Website
- nunabio.com/
- Ownership
- Privately Held (backing)
NunaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NunaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NunaBio in its N-PORT filings yet. We sweep new filings monthly.